Greiser Julia, Groeber Sebastian, Weisheit Thomas, Niksch Tobias, Schwab Matthias, Senft Christian, Kuehnel Christian, Drescher Robert, Freesmeyer Martin
Working Group for Translational Nuclear Medicine and Radiopharmacy, Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany.
Nuclear Medicine, Jena University Hospital, 07747 Jena, Germany.
Pharmaceuticals (Basel). 2023 Sep 7;16(9):1269. doi: 10.3390/ph16091269.
Radionuclide cisternography (RNC) is a method for conducting imaging of the cerebrospinal system and can be used to identify cerebrospinal fluid leaks. So far, RNC has commonly employed radiopharmaceutical agents suitable only for single-photon emission tomography techniques, which are thus lacking in terms of image resolution and can potentially lead to false-negative results. Therefore, [Cu]Cu-DOTA was investigated as an alternative radiopharmaceutical for RNC, employing positron emission tomography (PET) instead of single-photon emission tomography. A formulation of [Cu]Cu-DOTA was produced according to the guidelines for good manufacturing practice. The product met the requirements of agents suitable for intrathecal application. [Cu]Cu-DOTA was administered to a patient and compared to the approved scintigraphic RNC agent, [In]In-DTPA. While no cerebrospinal fluid leak was detected with [In]In-DTPA, [Cu]Cu-DOTA RNC exhibited a posterolateral leak between the vertebral bodies C1 and C2. Thus, in this patient, PET RNC with [Cu]Cu-DOTA was superior to RNC with [In]In-DTPA. Since radiopharmaceuticals have a very good safety profile regarding the occurrence of adverse events, PET RNC with [Cu]Cu-DOTA may become an attractive alternative to scintigraphic methods, and also to computed tomography or magnetic resonance imaging, which often require contrast agents, causing adverse events to occur much more frequently.
放射性核素脑池造影(RNC)是一种用于对脑脊液系统进行成像的方法,可用于识别脑脊液漏。到目前为止,RNC通常使用仅适用于单光子发射断层扫描技术的放射性药物,因此在图像分辨率方面存在不足,并且可能导致假阴性结果。因此,研究了[Cu]Cu-DOTA作为RNC的替代放射性药物,采用正电子发射断层扫描(PET)而非单光子发射断层扫描。[Cu]Cu-DOTA的制剂是根据药品生产质量管理规范指南生产的。该产品符合鞘内应用药物的要求。将[Cu]Cu-DOTA给予一名患者,并与已批准的闪烁扫描RNC药物[In]In-DTPA进行比较。虽然[In]In-DTPA未检测到脑脊液漏,但[Cu]Cu-DOTA RNC显示在C1和C2椎体之间存在后外侧漏。因此,在该患者中,使用[Cu]Cu-DOTA的PET RNC优于使用[In]In-DTPA的RNC。由于放射性药物在不良事件发生方面具有非常好的安全性,使用[Cu]Cu-DOTA的PET RNC可能成为闪烁扫描方法以及计算机断层扫描或磁共振成像的有吸引力的替代方法,后两者通常需要使用造影剂,会导致不良事件更频繁地发生。